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BB, 31% were due to failure to restart BB following hospitalization. More vigilance regard-
ing restoration of BB usage following hospital discharge is in order.
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1108-109 Low Hemoglobin Is an Independent Predictor of 
Adverse Fatal and Nonfatal Outcomes in Both Reduced 
and Preserved Systolic Function Chronic Heart Failure: 
Findings From the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity 
Program (CHARM)
John J. McMurray, Chim C. Lang, Karl Swedberg, Jan Östergren, Christopher B. 
Granger, Eric Michelson, James B. Young, Bertil Olofsson, Mark Dunlap, Salim Yusuf, 
Marc A. Pfeffer, for the CHARM Investigators, Western Infirmary, Glasgow, United 
Kingdom
Background: Low hemoglobin (Hb) is associated with higher mortality in patients with
chronic heart failure (CHF) and a reduced left ventricular ejection fraction (LVEF).
Whether Hb is an independent predictor of survival and also predicts non-fatal outcomes
is unclear. The importance of Hb in CHF and preserved LVEF is unknown.
Methods: The 3 CHARM trials were: i) CHARM-Alternative (n= 2028): LVEF < 0.40 intol-
erant of an ACE inhibitor (ACE-I) ii) CHARM-Added (n=2548): LVEF < 0.40 taking an
ACE-I iii) CHARM-Preserved (n=3025): LVEF > 0.40. Patients were randomised to pla-
cebo or candesartan and followed for 37.7 months. Outcomes were compared in those
with Hb < and > median (13.6g/dL).
Results: Unadjusted outcomes are shown in the table. In a multivariate analysis Hb was
an independent predictor of outcomes in both reduced LVEF and preserved LVEF CHF.
For the 2 low LVEF trials combined, the hazard ratios (HR) for > median versus < median
Hb were: Death 0.62 95% CI (0.51-0.75) p<0.0001; CHF hospitalization 0.72 (0.60-0.86)
p=0.0005 and death or CHF hospitalization 0.68 (0.58-0.78) p<0.0001. For CHARM-Pre-
served the HR were: 0.63 (0.46-0.86) p=0.004, 0.62 (0.47-0.81) p=0.0005 and 0.65
(0.52-0.81) p=0.0002, respectively.
Outcome in overall CHARM Programme according to whether baseline haemoglo-
bin was above or equal to/below median 
Conclusion: Hb is an independent predictor not only of death but also of CHF hospital-
ization. Hb is of as much prognostic significance in CHF with preserved LVEF as in CHF 
with a reduced LVEF.
1108-110 Pulmonary Edema Prognostic Score: A Novel Simple 
Prognostic Tool for Short-Term Events in Acute 
Cardiogenic Pulmonary Edema
Marcin Fiutowski, Tomasz Waszyrowski, Maria Krzeminska-Pakula, Jaroslaw D. 
Kasprzak, Medical University of Lodz, Lodz, Poland, Jonscher Hospital, Lodz, Poland
BACKGROUND: Cardiogenic pulmonary edema (CPE) is a common reason of hospitali-
sation connected with high mortality, but few data are published regarding long- and
short-term prognosis and no prognostic scales are in use.
AIM: To establish a simple score predicting the in-hospital prognosis in patients with
CPE.
METHODS AND RESULTS: We studied 276 Pts (148 females; mean age 70 years) hos-
pitalised due to CPO (hospital stay 12±7 days). In-hospital mortality was 21%. 44 clinical
variables were included in the analysis to revealthe most significant mortality predictors:
acute myocardial infarction (RR=2,12), heart rate:>115/min. (RR=2,13), systolic blood
pressure < 130mmHg (RR=3,61) and white blood cells>11500/mm3 (RR=2,26) on pre-
sentation. The number of risk factors was summed to create pulmonary edema prognos-
tic score (PEPS). PEPS had a linear relationship with mortality - figure. Pts with PEPS 0
had very good short-term prognosis with 2% in-hospital mortality rate (RR=0,07)
whereas mortality in Pts with PEPS 4 was 64% (RR=3,31). Receiver operating character-
istic curve analysis proved good discriminative ability (AUC= 0,78). Score above 1 had
sensitivity of 79%, specificity of 62%, 36% positive and 92% negative predictive value for
in-hospital mortality
CONCLUSIONS: Pulmonary edema prognostic score is a simple bedside tool allowing a
precise prediction of in-hospital prognosis after acute cardiogenic pulmonary edema.
1108-111 Serum Hyaluronic Acid Elevation in Patients With 
Decompensated Congestive Heart Failure Is 
Independent of Left Ventricular Systolic Function
Leonardo C. Clavijo, Daniel J. Cantillon, Jinguo Chen, Lurong Zhang, Michael D. 
Greenberg, Cynthia M. Tracy, Georgetown University, Washington, DC
BACKGROUND: Hyaluronic acid (HA), an extracellular glycosaminoglycan, is elevated
during hepatic hypoperfusion, edema and fibroproliferative disorders. Serum HA is 90%
metabolized and excreted by the liver. We have recently demonstrated that serum HA is
elevated in patients (pts) with decompensated CHF (dCHF).
HYPOTHESIS: Serum HA elevation in pts with clinically dCHF is independent of LV sys-
tolic function (LVSF) and CHF etiology (ischemic vs. non-ischemic), thus reflecting poor
hepatic perfusion and edema.
METHODS: A novel enzyme linked immunosorbent assay (ELISA) was used to measure
serum HA levels in two hundred pts consecutively admitted to the hospital. Fourteen pts
were excluded due to chronic liver disease or renal insufficiency. All dCHF pts were
symptomatic and the diagnosis confirmed by a cardiologist blinded to HA level. Based on
LVSF measured by echocardiogram, gated nuclear imaging or ventriculogram dCHF pts
were divided in two groups: dCHF + preserved LVSF (EF>40%) or dCHF + depressed
LVSF (EF <40%). Ischemic cardiomyopathy was identified by the presence or absence of
coronary disease in the setting of dCHF.
RESULTS: Admission serum HA levels were markedly elevated in pts with dCHF (259.0
ng/ml, SEM=49.5, n=32) vs. non-CHF pts (104.0 ng/ml, SEM=6.2, n=154), p<0.001.
Serum HA levels in pts with dCHF + preserved LVSF (348.5 ng/ml, SEM=106.2, n=14)
and dCHF + depressed LVF (189.4 ng/ml, SEM=24.4, n=18) were elevated compare to
non-CHF pts (104.0 ng/ml, SEM=6.2, n=154), p<0.001. The difference between dCHF
with preserved and depressed LVSF was not significant (p=0.11). There was no differ-
ence in HA levels between ischemic and non-ischemic dCHF groups (293.3 ng/ml,
SEM=71.9, n=21 vs. 193.3 ng/ml, SEM=41.3, n=11), p=0.27.
CONCLUSION: Serum hyaluronic acid level is elevated in pts with symptomatic clinically
dCHF. HA elevation is independent of left ventricular systolic function and ischemic etiol-
ogy. Further studies are needed to investigate the mechanisms and prognostic value of
HA elevation during dCHF.
1108-112 An Embolic Event to Death in More Than 50 Percent of 
Patients With Idiopathic Dilated Cardiomyopathy in End- 
Stage Heart Failure
Antonio C. Barretto, Sr., Mucio T. Oliveira Jr, Sr., Robinson T. Munhoz, Sr., Airton R. 
Scipioni, Sr., Maria L. Higuchi, Jose A F Ramires, Sr., Heart Institute, (InCor), University 
of São Paulo Medical School, São Paulo, Brazil
Background: Pts with idiopathic dilated cardiomyopathy (IDC) and end stage heart failure
has a worse prognosis with high mortality. Embolic events (EE) could contribute to the
heart failure bad evolution of these pts.
Objective: To clarify the importance of EE in the evolution of pts with IDC, we analyzed
the data from necropsies of heart failure pts that died at the hospital in the last ten years.
Methods: Between 1990 and 1999, 3847 necropsies were performed and 118 pts had
IDC. The pts mean age was 41.8 years and 74 (62,7%) were male. The echocardiogram
showed a mean LV end diastolic diameter of 76,0 mm and a mean LV ejection fraction of
0,32. Results: EE were identified in 90 (76,3%) pts, 61 (51,7%) of those had pulmonary
embolism (PE), 29 (24,6%) systemic embolism (SE) and 33 (14.2%) both. The great
majority of EE was not diagnosis in life. Cardiac thrombus was detected in right cham-
bers in 26 pts (22,0%) and in left chambers in 18 (24,62%). The main embolic source
Hb > median
(n=1368)
Hb <
median
(n=1281)
Outcome (%)
death 19.0 27.9
CHF hospitalization 22.5 30.3
Death or CHF hospitalization 33.5 44.9
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was cardiac. Pts with atrial fibrillation (AF) and cardiac thrombus were more prone to
present an EE. The mean heart weight was 663.3 g, with no difference between those
with or without EE. There was no correlation also between LV diastolic diameter and
ejection fraction and EE.
Conclusions: EE were very frequent in pts with IDC, namely more than 50% of pts with
DCM that died at the hospital presented one or more EE. Our findings support the indica-
tion to anticoagulation for pts with AF and cardiac thrombi, but the degree of left ventricu-
lar dysfunction was not a good predictor of EE.
1108-113 Flow-Mediated Vasodilatation Predicts Outcome in 
Patients With Chronic Heart Failure
Brigitte Meyer, Martin Huelsmann, Karin Strecker, Thomas Neunteufl, Richard Pacher, 
Rudolf Berger, University Medical School of Vienna, Vienna, Austria
Background: Chronic heart failure (CHF) is associated with reduced endothelium-depen-
dent, flow mediated vasodilatation (FMD). The prognostic impact of this observation,
however, is unknown. The aim of the study was to assess the predictive potency of
impaired FMD in patients with CHF.
Methods: 75 CHF patients with a left ventricular ejection fraction (LVEF) < 30% despite
optimised medical therapy (angiotensin converting encyme inhibitor and angiotensin II
receptor blocker 100%, beta-blocker 81%) were evaluated. Using high resolution ultra-
sound, FMD of the brachial artery was assessed in addition to other neurohormonal, clin-
ical and hemodynamic variables. Age, gender, NYHA functional class, LVEF,
hemodynamic variables, natriuretic peptides, medical therapy, cardiovascular risk factors
and FMD were analysed for prediction of the combined endpoint death and HTx in a mul-
tivariate Cox model.
Results: Up to three years, 44 patients survived, 14 patients died and 17 patients under-
went urgent heart transplantation (HTx). Univariate risk factors for adverse outcome were
FMD (p=0.0044), log BNP (p=0.0063), log N-terminal ANP (p=0.0151), mean blood pres-
sure (p=0.0182), NYHA class (p=0.0216) and beta-blocker therapy (p=0.0429). In the
multivariate analysis, only FMD (p=0.0044) and log BNP (p=0.0030) were independently
related to adverse outcome. In the Kaplan-Meier blot, significantly more patients with a
FMD < 5.3% (median) reached the combined endpoint compared with patients with a
FMD > 5.3% (p=0,0007).
Conclusion: In CHF impaired FMD is a strong, independent predictor of adverse out-
come.
1108-114 The Relationship Between the VAS on the EQ-5D and 
the Kansas City Cardiomyopathy Questionnaire in 
Patients With Acute Myocardial Infarction Complicated 
by Heart Failure
Zefeng Zhang, John A. Spertus, Philip Jones, William S. Weintraub, Emory University 
School of Medicine, Atlanta, GA, Mid-America Heart Institute and the University of 
Missouri, Kansas, MO
Background: The EPHESUS trial was designed to evaluate the effect of eplerenone on
outcomes among patients with heart failure (HF) complicating acute myocardial infarction
(AMI). We sought to examine the relationship between utility and HF-related health sta-
tus in this patient population.
Methods: Utility was evaluated with visual analogue score (VAS) on the EQ-5D, an instru-
ment designed to measure patients’ preference values for a wide range of standardized
health states. Kansas City Cardiomyopathy Questionnaires (KCCQ), a 23-item health
status measure for HF, was used to evaluate HF-related quality of life. Questionnaires
were administered to 2280 patients at baseline, 1 month and 1 year.
Results: Scores for both utility and KCCQ overall summary score improved significantly
from baseline at 1 and 12 months (see Table). 
KCCQ overall summary score quartiles (<=42.3 (n=383), >42.3 to 62.5 (n=396), >62.5 to
82.3 (n=387), >=82.3 (n=383)) were significantly associated with EQ-5D scores
(46.4±19.0, 56.1±18.5, 63.5±18.2, 70.1±18.0; p<0.0001). Multivariate analysis adjusting
for age, gender and country indicated KCCQ scores to be the strongest independent pre-
dictor of the utility scores. Improvement in 1-year utility scores was significantly corre-
lated with improved 1-year KCCQ scores (r=0.45, p<0.0001).
Conclusions: While KCCQ is an important and independent predictor of utility scores in
patients with HF complicating AMI, it probably can not be used as proxy measure for util-
ity.
1108-115 Right Ventricular Function Recovery After Acute 
Myocardial Infarction: The Relation With Left Ventricular 
Function and Interventricular Septum Motion-The 
GISSI-3 Echo Substudy
Bogdan A. Popescu, Francesco Antonini-Canterin, Pantaleo Giannuzzi, Pier L. 
Temporelli, Enzo Bosimini, Francesco Gentile, Aldo P. Maggioni, Luigi Tavazzi, Rita 
Piazza, Luigi Ascione, Ioana Stoian, Eugenio Cervesato, Andreea C. Popescu, Gian L. 
Nicolosi, Centro Studi ANMCO, Firenze, Italy
Background. The pattern of right ventricular (RV) function recovery and its relation with
left ventricular (LV) function changes and interventricular septum (IVS) motion in low risk
patients after acute myocardial infarction (AMI) have not been assessed yet.
Methods. We studied a group of 500 patients (414 men, 60.8 ± 11.8 years) from the
GISSI-3 Echo Substudy, who survived 6 months after AMI and who underwent serial
echocardiograms at a mean of 36 ± 8 hours from symptom onset (S1), at hospital dis-
charge (mean 12 ± 5 days, S2), at 6 weeks (S3), and at 6 months (S4). The echocardio-
grams were analyzed in the Core Laboratory by experts blinded to all clinical data.
Tricuspid annular plane systolic excursion (TAPSE) was measured by 2-D echocardio-
graphy for RV systolic function assessment. The wall motion score index (WMSI) was
calculated for the whole LV (16 segments): global WMSI, for the IVS (5 segments): IVS-
WMSI, and for the LV free wall (11 segments). Changes in echocardiographic parame-
ters during follow-up (S4-S1), and the determinants of TAPSE at S1 and of TAPSE
changes were calculated.
Results. There was a significant increase in TAPSE during follow-up (from 1.79 ± 0.46 cm
at S1 to 1.92 ± 0.46 cm at S4, time effect: F=25, p<0.001), which was already significant
at S2 (1.88 ± 0.47 cm, time effect: F=26.7, p<0.001). LV ejection fraction (LVEF) was the
best correlate of TAPSE at S1 (r=0.15, p=0.001). Although at univariate analysis TAPSE
changes correlated with LVEF changes (r=0.12, p=0.008), with global WMSI changes (r=
- 0.11, p=0.013), and with IVS-WMSI changes (r= - 0.12, p=0.005), by multivariate analy-
sis IVS-WMSI changes emerged as the only independent predictor of TAPSE changes
during follow-up (r= - 0.12, p=0.007).
Conclusion. In low-risk patients after AMI, recovery in RV function occurs throughout 6-
month follow-up and is already significant at discharge. TAPSE is significantly related to
LVEF at S1. Changes in RV function during 6-month follow-up are related to global and
regional LV function changes, and best to IVS-WMSI improvement. This suggests that
IVS motion itself and IVS-mediated ventricular interaction are important mechanisms of
RV function improvement in this setting.
1108-116 Cardiac Power Output Is the Only Independent 
Hemodynamic Predictor of Outcome in Acute Heart 
Failure
Gad Cotter, Nir Uriel, Loic Perchenet, Edo kaluski, Isaac Kobrin, Aline Frey, Olga Milo, 
Alex Blatt, Shoshana Kaplan, Zvi Vered, Guillermo Torre-Amione, Assaf-Harofeh Medical 
Center, Zerifin, Israel, Methodist Hospital at Baylor College of Medicine, Houston, TX
In recent years the use of right heart catheterization for the stratification of patients with
acute heart failure has diminished, primarily since cardiac hemodynamics showed rather
poor correlation with outcome.
Methods: The purpose of the present study was to assess the predictive value of hemo-
dynamic variables at admission in conjunction with clinical variables in 120 patients
admitted with acute heart failure that underwent right heart catheterization at admission.
Patients were in the placebo arms of two multicenter international studies. We assessed
hemodynamic and clinical variables up to 30 days. In addition cardiac power output
(CPo) was calculated as CO *mean arterial blood pressure (MAP) and expressed in Watt
units.
Conclusion: Cardiac Power Output was the strongest hemodynamic predictor of recur-
rent heart failure events in patients admitted due to acute heart failure. Wedge pressure
had no correlation with recurrent events.
1108-117 Reduced Bone Mass in Men With Advanced Chronic 
Heart Failure Is Accompanied by Hyperparathyroidism, 
Andropenia, and Inflammation, and Predicts Poor 
Outcome
Ewa A. Jankowska, Agnieszka Kus, Justyna Jakubaszko, Jacek Majda, Waldemar 
Banasiak, Stefan Anker, Piotr Ponikowski, Military Hospital, Wroclaw, Poland, National 
Heart and Lung Institute, London, United Kingdom
Background Cardiac cachexia in patients (pts) with chronic heart failure (CHF) is
defined as deficiency of lean and fat tissues. Bone status as marker of cachexia in CHF
has not been studied.
Methods We examined bone mineral content (BMC) in arms, legs, trunk, total body
using dual energy X-ray absorptiometry in 123 consecutive male CHF pts (age: 59 ± 1 y,
LVEF: 31 ± 1 %, NYHA class I/II/III/IV: 10/61/40/12) and 37 men without CHF (age: 55 ±
1 y, LVEF: 59 ± 1 %). T-score (BMC compared to BMC of young adults, in standard devi-
ation units [SD]) and Z-score (BMC compared to BMC of age-matched healthy men, in
SD) were calculated.
Results CHF pts had reduced all BMC when compared to pts without CHF (all p<0.05).
CHF severity was related to reduction of all BMC (BMCtotal: 3.3 ± 0.1 / 3.0 ± 0.1 / 2.8 ±
0.1 / 2.5 ± 0.1 kg, NYHA I/II/III/IV, r = -0.23, p<0.01), T-score (0.5 ± 0.4 / -0.3 ± 0.1 / -0.4
Baseline 1 month 12 months p value
KCCQ scores 60.8 (n=1616) 68.8 (n=1516) 78.0 (n=1229) <0.001
EQ-5D scores 59.0 (n=1551) 66.4 (n=1470) 73.0 (n=1216) <0.001
7 Days Recurrent 
WHF
30 Days 
Recurrent WHF
Variables RR (95% CI) P Value RR (95% CI) P Value
Age 1.3 (0.65-2.7) 0.44 1.3 (0.68-2.5) 0.42
Body Mass Index 0.79 (0.41-1.5) 0.47 0.72 (0.4-1.3) 0.3
Creatinine 0.76 (0.39-1.46) 0.41 0.64 (0.35-1.12) 0.15
Cardiac Index 0.73 (0.39-1.46) 0.41 0.74(0.39-1.4) 0.32
Cardiac Output 0.68 (0.34-1.35) 0.27 0.7 (0.37-1.3) 0.26
Cardiac Power Output 0.47 (0.24-0.93) 0.0029 # 0.55 (0.3-1.03) 0.06
Wedge Pressure 1.4 (0.69-3) 0.33 1.44 (0.7-2.6) 0.36
Peripheral Vascular 
resistance
1.55 (0.78-3.1) 0.21 1.4 (0.7-2.6) 0.36
Mean Arterial Blood 
Pressure
0.6 (0.3-1.2) 0.15 0.6 (0.3-1.2) 0.15
Sex (Female) 0.63 (0.32-1.24) 0.18 0.66 (0.35-1.2) 0.19
